CYTK Cytokinetics Inc.

XNAS 55.54 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CYTK $55.54 —
Key stats
$55.54
52-Week Range
$53.55 – $88.31
YTD
-10.03%
IV Rank (30D)
53.47
Straddle Price
$7.10
P/C Vol Ratio
0.32
Market Cap
$7.5B
Open
$54.38
Day Range
$53.58 – $55.68
Volume
1,644,114
Prev Close
$53.69
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY0.90
Cost of Equity (CAPM)9.38% (VRP-adj)
WACC8.84%
Volatility Risk Premium+17.0pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.6B
Return on Equity (TTM)515.3%
Book / Price-2.4%
Gross Margin (TTM)92.2%
FCF Margin (TTM)-858.2%
Quality Score3/6 — normal (10y DCF)
SMA 50$65.67 (Market Anchor value)
SMA 20 / Bollinger Mid$61.69
Bollinger Width / SMA2016.4% (drives anchor stability)
Net Debt$0.9B
Market Cap$7B
Peers used for multiples: COGT, GH, ISRG, LLY, RVMD, TVTX, TWST, VRTX
60-Day Conviction
73%
20-Day Fair Value
≈ by Dec 8, 2026
$55.72
α +0.5% rank 22%
conviction
39%
40-Day Fair Value
≈ by Jan 6, 2027
$56.59
α +2.1% rank 33%
conviction
66%
60-Day Fair Value
≈ by Feb 4, 2027
$57.26
α +3.3% rank 27%
conviction
73%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 44.1× · 3 peers
Peer EV/EBITDA n/a 0% median 29.7× · 3 peers
Peer P/B n/a 0% median 16.0× · 7 peers
Peer P/S $8.06 11% median 14.3× · 7 peers
Market Anchor (SMA50) $65.67 51% stability 68% (BB-width)
Options Expected (B-L 30d) $53.93 38% 21 strikes · skew -0.40
As of 2026-11-09 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$7.5B
Employees
673
List Date
2004-04-29
CIK
0001061983
Last Earnings
Nov 4 after close · −12.7% vs ±10.9% expected
Next Earnings
~Feb 23, 2027 (estimated)
Headquarters
South San Francisco, CA
Homepage
https://www.cytokinetics.com

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is develo…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan0.56%-27.85%-4.22%-7.12%1.08%2.37%-5.86%
Feb-7.23%5.21%1.24%-11.09%-5.09%-4.51%-3.58%
Mar18.31%2.39%-18.37%-5.23%-6.30%7.29%-0.32%
Apr4.09%3.88%-0.82%-16.02%14.24%-3.96%0.24%
May-15.78%-0.08%-0.21%-23.45%-27.73%21.17%-7.68%
Jun-8.80%-2.92%-14.07%8.64%5.86%15.62%0.72%
Jul41.47%3.24%-0.03%7.88%11.89%-9.32%9.19%
Aug14.60%28.83%7.51%-1.43%-3.71%-7.25%6.42%
Sep8.24%-9.84%-18.17%-3.23%10.76%-7.69%-3.32%
Oct-4.98%-14.58%25.04%-3.04%13.88%-4.01%2.05%
Nov14.53%-1.14%-4.62%0.08%13.49%-10.65%*1.95%
Dec23.49%12.14%148.70%-7.09%-3.80%--34.69%
Total108.10%-11.06%75.61%-49.29%16.56%-6.04%22.31%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $61.32
SMA 50: $65.34
SMA 200: $69.93
Current: $55.48
EMA 12: $59.55
EMA 26: $61.82
MACD: -2.2679 | Signal: -0.5281
BEARISH
ADX (14): 26.30
TREND
+DI: 10.97
−DI: 30.77

Momentum Oscillators

RSI (14): 33.26
NEUTRAL
Stoch %K: 10.32
Stoch %D: 26.82
Williams %R: -83.13

Volume & Volatility

BB Upper: $67.04
BB Lower: $55.61
OVERSOLD
OBV: 1,982,046
Vol SMA 20: 1,852,629
Vol ROC: 109.06%
ATR: $2.69
True Range: $2.10
HV 20: 57.9%
HV 30: 49.4%
HV 60: 42.8%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before CYTK’s Nov 4 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Recent positive news headlines highlighting clinical trial results and company announcements
  • Bullish momentum signals from MACD and RSI indicators
  • Moderate volatility, indicating a relatively stable market environment

Primary Risks:

  • Potential for mean reversion if current technical levels are unsustainable
  • Regulatory or clinical trial setbacks that could impact stock performance

Investment Thesis:

Cytokinetics (CYTK) appears to be in a consolidation phase, with recent news headlines and technical indicators suggesting potential upside. The company's Aficamten therapy has shown promising results in clinical trials, which could drive growth prospects. However, the options market is pricing in a relatively low volatility environment, which may not fully capture the stock's potential.

Recent News Sentiment Impact:

The recent positive news headlines have contributed to the bullish sentiment, with the majority of articles highlighting the company's progress and potential for future growth.

Technical Analysis

Trend Direction: Short-term (1-4 weeks) - NEUTRAL

Support/Resistance Levels:

  • SMA 20: $73.41
  • SMA 50: $76.75
  • Upper Bollinger Band: $79.45
  • Lower Bollinger Band: $67.37

Momentum Signals:

  • MACD signal line is below the zero line, indicating bearish momentum (but with a relatively low negative value)
  • RSI is neutral at 35.13%, suggesting no clear overbought or oversold conditions

Volume Analysis:

  • Volume SMA 20: 1955748.80
  • On-Balance Volume (OBV) is increasing, suggesting accumulation
  • Volume Rate of Change is high at 206.53%, indicating strong buying pressure

News & Sentiment Analysis

Recent Headlines Summary:

The past week has seen a series of positive news headlines highlighting the company's progress and potential for future growth.

Sentiment Assessment: POSITIVE (Confidence Level: 8/10)

Catalyst Identification:

  • Upcoming investor conferences
  • Ongoing clinical trials and results announcements

Market Narrative:

The recent news headlines align with the technical signals, suggesting a potential uptrend. However, the MACD signal line is still below the zero line, indicating some caution.

Risk & Volatility Assessment

Beta Interpretation: 0.90 (Moderate risk relative to market)

Volatility Regime: Current vs historical volatility levels - MODERATE

Options Market Signals:

  • IV Rank: 23.1% (Low)
  • Current IV: 64.9%
  • Expected Move: $6.53 (28 DTE), 7-DTE: $1.05
  • Volume Flow: 1,049 calls vs 554 puts
  • Open Interest: 1,378 calls vs 1,126 puts

Downside Protection:

Support levels are relatively strong at the lower Bollinger Band ($67.37) and SMA 20 ($73.41). However, the risk of a technical breakdown is still present.

Market Context & Positioning

Sector Performance: CYTK has outperformed its sector peers over the past month

Institutional Activity:

  • Volume patterns suggest institutional interest in the stock
  • On-Balance Volume (OBV) is increasing, indicating accumulation

Correlation Analysis:

The stock has a moderate correlation with the market (R-squared interpretation), suggesting some independence from broader market trends.

Relative Valuation:

CYTK appears to be trading within its historical range, suggesting no clear overvaluation or undervaluation.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $73.41
  • Upper Bollinger Band: $79.45

Breakout/Breakdown Levels:

  • Resistance at the upper Bollinger Band ($79.45)
  • Support at the lower Bollinger Band ($67.37)

Time-Sensitive Catalysts:

  • Upcoming investor conferences
  • Ongoing clinical trials and results announcements

Risk Management:

Consider setting a stop-loss level around $72.50 to manage potential downside risk.

Please let me know if you would like me to elaborate on any of the points or if you have any specific questions!

Generated
News
All CYTK news →
Earnings History
20 of 23 under expected move
Avg Expected Move
12.79%
Avg Actual Move
4.99%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-25 After-Close 23.68% 5.64% 0.24x Within
2021-05-06 After-Close 25.25% 3.68% 0.15x Within
2021-07-21 After-Close 17.96% 2.80% 0.16x Within
2021-11-03 After-Close 11.86% 6.27% 0.53x Within
2022-02-24 After-Close 15.46% 3.15% 0.20x Within
2022-05-04 After-Close 12.55% 1.68% 0.13x Within
2022-08-04 After-Close 6.64% 10.92% 1.64x Exceeded
2022-11-03 After-Close 11.32% 5.03% 0.44x Within
2023-03-01 After-Close 14.22% 8.14% 0.57x Within
2023-05-04 After-Close 11.84% 0.38% 0.03x Within
2023-08-03 After-Close 12.40% 4.70% 0.38x Within
2023-11-02 After-Close 11.69% 4.85% 0.41x Within
2024-02-27 After-Close 6.54% 9.75% 1.49x Exceeded
2024-05-08 After-Close 7.02% 1.92% 0.27x Within
2024-08-08 After-Close 17.04% 3.31% 0.19x Within
2025-02-27 After-Close 16.17% 3.06% 0.19x Within
2025-05-06 After-Close 11.78% 2.74% 0.23x Within
2025-08-07 After-Close 7.09% 3.23% 0.46x Within
2025-11-05 After-Close 10.60% 1.88% 0.18x Within
2026-02-24 After-Close 11.48% 10.29% 0.90x Within
2026-05-05 After-Close 11.61% 2.92% 0.25x Within
2026-08-06 After-Close 9.16% 5.67% 0.62x Within
2026-11-04 After-Close 10.89% 12.66% 1.16x Exceeded

Earnings calendar: this week’s reports with expected vs actual moves →

CYTK Options Activity & IV Rank

CYTK IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 50.9%
7-DTE IV: 55.8%
Expected Move: $7.10
7-DTE Move: $4.28
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 5,567
Put Volume: 1,801
P/C Volume: 0.324
BULLISH
Call OI: 70,889
Put OI: 12,694
P/C OI: 0.179
Total OI: 83,583

ATM Options Pricing

ATM Call: $3.45
ATM Put: $3.65
Call %: 6.2%
Put %: 6.6%

Chain Summary

Chain Volume: 7,368
Chain OI: 83,583
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 3rd percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
3%
vs own history
GEX tilt
-0.47
OI-weighted, today
Vanna tilt
+0.02
δ-sensitivity to IV
Charm tilt
+0.13
δ-decay vs time

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 20 ATM contracts, 6k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)9.0LowNov 9
IV Rank (30 DTE)53.5MediumNov 9
Straddle Price (30 DTE)$7.10Nov 9
Beta Analysis

Risk Metrics

Beta: 1.0038
Alpha: -11.15%
Correlation: 0.3139
R-Squared: 9.9%
Stock Volatility: 44.0%
Market Volatility: 13.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own CYTK
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Point72 Hedge fund
Steve Cohen
$135.3M
0.21%
#123 of 1945+153.6%13F
Citadel Hedge fund
Ken Griffin
$54.6M
0.03%
#647 of 6285-41.7%13F
Millennium Management Hedge fund
Izzy Englander
$9.3M
0.01%
#1621 of 3716+12.0%13F
Rockefeller Capital Management Family office
Rockefeller family
$271K
0.00%
#2436 of 4729+10.9%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

CYTK Institutional Ownership (13F)

Filings for 2026-06-30 · 183 already for 2026-09-30
Diluted shares outstanding: 123,861,000 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

503 filers443,629,060 shares$27.06B value358.17% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 40,188,724 $3.42B 12.65% 32.45% 2026-06-30
2 T. Rowe Price Investment Management, Inc. 37,436,996 $3.19B 11.79% 30.23% 2026-06-30
3 Wellington Management Group LLP Custodian 17,643,540 $1.19B 4.39% 14.24% 2026-06-30
4 Vanguard Portfolio Management LLC 13,423,598 $1.14B 4.23% 10.84% 2026-06-30
5 State Street Corp 12,988,466 $1.11B 4.09% 10.49% 2026-06-30
6 Vanguard Capital Management LLC 12,235,030 $1.04B 3.85% 9.88% 2026-06-30
7 FMR LLC Custodian 11,668,564 $860.04M 3.18% 9.42% 2026-06-30
8 Avoro Capital Advisors LLC 9,999,998 $851.90M 3.15% 8.07% 2026-06-30
9 Bank of America Corp Custodian 19,859,418 $807.83M 2.99% 16.03% 2026-06-30
10 Geode Capital Management, LLC Custodian 7,535,728 $496.77M 1.84% 6.08% 2026-09-30
11 RTW INVESTMENTS, LP 5,724,006 $487.63M 1.80% 4.62% 2026-06-30
12 Polar Capital Holdings Plc 4,507,298 $383.98M 1.42% 3.64% 2026-06-30
13 T. Rowe Price Associates, Inc. 3,917,892 $333.77M 1.23% 3.16% 2026-06-30
14 Goldman Sachs Group Inc Custodian 6,718,176 $305.57M 1.13% 5.42% 2026-06-30
15 Capital Research Global Investors 3,373,250 $287.37M 1.06% 2.72% 2026-06-30
16 Northern Trust Corp Custodian 3,294,690 $280.67M 1.04% 2.66% 2026-06-30
17 JPMorgan Chase & Co Custodian 3,327,790 $278.54M 1.03% 2.69% 2026-06-30
18 Integral Health Asset Management, LLC 3,200,000 $272.61M 1.01% 2.58% 2026-06-30
19 Point72 Asset Management, L.P. 3,175,424 $270.51M 1.00% 2.56% 2026-06-30
20 Charles Schwab Investment Management, Inc. 3,131,562 $266.78M 0.99% 2.53% 2026-06-30
21 Morgan Stanley Custodian 8,101,636 $265.96M 0.98% 6.54% 2026-06-30
22 Susquehanna International Group, LLP Custodian 3,098,916 $264.00M 0.98% 2.50% 2026-06-30
23 Capital International Investors 2,611,696 $222.49M 0.82% 2.11% 2026-06-30
24 Invesco Ltd. Custodian 2,470,646 $210.47M 0.78% 1.99% 2026-06-30
25 WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 3,152,270 $207.77M 0.77% 2.54% 2026-09-30
22 filers$1.15B notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $322.12M 27.91% 2026-06-30
2 ARMISTICE CAPITAL, LLC $260.68M 22.59% 2026-06-30
3 Citadel Advisors LLC Custodian $154.13M 13.36% 2026-06-30
4 Jane Street Group, LLC Custodian $119.27M 10.34% 2026-06-30
5 Caption Management, LLC $87.30M 7.57% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $64.02M 5.55% 2026-06-30
7 Lombard Odier Asset Management (Europe) Ltd $26.99M 2.34% 2026-06-30
8 TUDOR INVESTMENT CORP ET AL $22.56M 1.95% 2026-06-30
9 Millennium Management LLC Custodian $17.06M 1.48% 2026-06-30
10 SILVERBACK ASSET MANAGEMENT LLC $17.04M 1.48% 2026-06-30
11 SPHERA FUNDS MANAGEMENT LTD. $17.04M 1.48% 2026-06-30
12 PEAK6 LLC $7.87M 0.68% 2026-06-30
13 Walleye Trading LLC $7.58M 0.66% 2026-06-30
14 IMC-Chicago, LLC Custodian $7.14M 0.62% 2026-09-30
15 Goldman Sachs Group Inc Custodian $5.64M 0.49% 2026-06-30
16 Simplex Trading, LLC Custodian $3.76M 0.33% 2026-09-30
17 Balyasny Asset Management L.P. $3.31M 0.29% 2026-06-30
18 JPMorgan Chase & Co Custodian $3.05M 0.26% 2026-06-30
19 Walleye Capital LLC $2.47M 0.21% 2026-06-30
20 Citigroup Inc. Custodian $2.37M 0.21% 2026-09-30
21 DLD Asset Management, LP $1.70M 0.15% 2026-06-30
22 Centiva Capital, LP $851.90K 0.07% 2026-06-30
15 filers$190.50M notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $71.76M 37.67% 2026-06-30
2 Susquehanna International Group, LLP Custodian $49.34M 25.90% 2026-06-30
3 Jane Street Group, LLC Custodian $25.47M 13.37% 2026-06-30
4 LMR Partners LLP $11.40M 5.98% 2026-06-30
5 Walleye Trading LLC $8.96M 4.70% 2026-06-30
6 DIADEMA PARTNERS LP $5.11M 2.68% 2026-06-30
7 TUDOR INVESTMENT CORP ET AL $3.80M 1.99% 2026-06-30
8 Bank of Montreal Custodian $3.41M 1.79% 2026-06-30
9 GROUP ONE TRADING LLC Custodian $3.31M 1.74% 2026-06-30
10 Walleye Capital LLC $2.96M 1.56% 2026-06-30
11 Citigroup Inc. Custodian $2.37M 1.25% 2026-09-30
12 IMC-Chicago, LLC Custodian $2.13M 1.12% 2026-09-30
13 Simplex Trading, LLC Custodian $276.82K 0.15% 2026-09-30
14 Point72 Asset Management, L.P. $102.23K 0.05% 2026-06-30
15 Persistent Asset Partners Ltd $81.50K 0.04% 2026-06-30

CYTK Insider Trading (Form 4)

Latest: 2026-11-03
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-03 Fady Ibraham Malik EVP Research & Development Mixed
Exer +3,500 · Sell −3,500
 — $35.37 -$193.0K EDGAR
2026-11-02 Robert I Blum President & CEO Mixed
Exer +7,500 · Sell −7,500
 — $36.70 -$391.6K EDGAR
2026-10-20 Robert Arthur Harrington Director Award (A) +195 $63.92 $12.5K EDGAR
2026-10-20 Wendell Wierenga Director Award (A) +97 $63.92 $6.2K EDGAR
2026-10-20 Edward M. MD Kaye Director Award (A) +195 $63.92 $12.5K EDGAR
2026-10-20 Fady Ibraham Malik EVP Research & Development Mixed
Exer +3,500 · Sell −3,500
 — $35.91 -$196.7K EDGAR
2026-10-20 James M Daly Director Award (A) +195 $63.92 $12.5K EDGAR
2026-10-20 Nancy Wysenski Director Award (A) +97 $63.92 $6.2K EDGAR
2026-10-20 John T Henderson Director Award (A) +352 $63.92 $22.5K EDGAR
2026-10-13 Robert I Blum President & CEO Mixed
Exer +7,500 · Sell −7,500
 — $36.74 -$392.1K EDGAR
2026-10-06 Fady Ibraham Malik EVP Research & Development Mixed
Sell −3,500 · Exer +3,500
 — $34.59 -$187.5K EDGAR
2026-09-28 Robert I Blum President & CEO Mixed
Sell −7,500 · Exer +7,500
 — $38.03 -$411.4K EDGAR
2026-09-22 Fady Ibraham Malik EVP Research & Development Mixed
Sell −3,500 · Exer +3,500
 — $38.05 -$211.7K EDGAR
2026-09-15 Robert E Landry Director Sell (S) −1,000 $72.13 -$72.1K EDGAR
2026-09-15 Robert I Blum President & CEO Mixed
Gift −1,350 · Exer +7,500 · Sell −105,426
 −99,276 $65.70 -$7.26M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

CYTK Insider Holdings

16 insiders · @ $55.48
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Robert I Blum President & CEO 280,627 $15.57M -$61.86M 252 2026-11-02
2 Fady Ibraham Malik EVP Research & Development 153,902 $8.54M -$33.69M 159 2026-11-03
3 Jeffrey Hessekiel Chief Legal & Admin Officer 107,943 $5.99M $0 2 2026-03-17
4 John T Henderson Director 78,795 $4.37M -$5.67M 74 2026-10-20
5 Sung Lee EVP, Chief Financial Officer 64,333 $3.57M -$5.70M 12 2026-07-02
6 Andrew Callos EVP, Chief Commercial Officer 58,555 $3.25M -$18.98M 44 2026-08-31
7 Wendell Wierenga Director 35,660 $1.98M -$1.88M 9 2026-10-20
8 Nancy Wysenski Director 34,089 $1.89M $0 31 2026-10-20
9 Wendall Wierenga Director 32,345 $1.79M -$2.52M 49 2025-07-16
10 Muna Bhanji Director 26,361 $1.46M -$215.6K 14 2026-05-27
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

CYTK Board & Officers

As of SEC filings through Nov 3, 2026

Directors 11

Officers 5

Changes in the last 10 years (43)
Nov 13, 2025Jeffrey Hessekiel became Chief Legal & Admin Officer
Oct 21, 2025Wendell Wierenga first on file as a director
Aug 19, 2025James M Daly became a director
Feb 10, 2025Robert E Landry became a director
Dec 16, 2024The company announced the departure of Robert Wong as VP, Chief Accounting Officer in an SEC filing
Nov 1, 2024The company announced the departure of Santo J Costa from the board in an SEC filing
Aug 13, 2024Brett A Pletcher became EVP, Chief Legal Officer
May 15, 2024The company announced the departure of Sandford D Smith from the board in an SEC filing
Apr 26, 2024Sung Lee became EVP, Chief Financial Officer
Jan 29, 2024The company announced the departure of Ching Jaw as SVP Finance & CFO in an SEC filing
Apr 12, 2022The company announced the departure of Mark A Schlossberg as SVP - Legal & General Counsel in an SEC filing
Apr 8, 2022The company announced the departure of L Patrick Gage from the board in an SEC filing
Apr 8, 2022Robert Arthur Harrington became a director
Feb 17, 2022Andrew Callos listed as EVP, Chief Commercial Officer (previously Chief Commercial Officer) in SEC filings
Feb 16, 2022The company announced the departure of Robert Califf from the board in an SEC filing
Jun 2, 2021David Cragg listed as Chief HR & Admin Officer (previously SVP Human Resources) in SEC filings
Mar 15, 2021Andrew Callos became Chief Commercial Officer
Feb 17, 2021Muna Bhanji became a director
Dec 11, 2020Mark N Lampert reported in an SEC filing no longer being a 10% owner
Dec 11, 2020Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner
Not reported recently (9)
  • Brett A Pletcher · Last reported as EVP, Chief Legal Officer in an SEC filing dated Sep 3, 2024
  • David Cragg · Last reported as Chief HR & Admin Officer in an SEC filing dated Mar 8, 2022
  • Caryn Gordon McDowell · Last reported as GC & Chief Compliance Officer in an SEC filing dated Mar 1, 2018
  • Peter S Roddy · Last reported as SVP Finance & CAO in an SEC filing dated Mar 1, 2018
  • Bradley Paul Morgan · Last reported as SVP Drug Discovery & Early Dev in an SEC filing dated Sep 1, 2017
  • Andrew A Wolff · Last reported as SVP & CMO in an SEC filing dated Mar 2, 2017
  • Sharon Surrey Barbari · Last reported as EVP, Finance & CFO in an SEC filing dated Mar 2, 2017
  • Bonnie Charpentier · Last reported as SVP Regulatory & Compliance in an SEC filing dated Mar 2, 2017
  • Elisabeth Schnieders · Last reported as Sr. VP, Business Development in an SEC filing dated Mar 2, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

CYTK Proposed Insider Sales (Form 144)

Latest: 2026-10-20
Last 30d: 2 filings · $2.4M notice value  ·  Last 90d: 5 filings · $10.0M notice value · 4 unique filers · 80% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Robert I. Blum (2, $8.5M) · FADY MALIK (1, $1.0M) · B LYNNE PARSHALL (1, $355K) · ROBERT LANDRY (1, $147K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-20 FADY MALIK Officer 16,386 $1.03M 2026-10-20 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-10-13 ROBERT BLUM Director, Officer 22,500 $1.42M 2026-10-12 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-15 Robert I. Blum President, CEO, Director 97,926 $7.09M 2026-09-15 J.P. Morgan Securities LLC — EDGAR
2026-09-11 ROBERT LANDRY Director 2,000 $147.2K 2026-09-11 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-01 B LYNNE PARSHALL Director 5,000 $354.6K 2026-09-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-30 ANDREW CALLOS Officer 24,000 $1.88M 2026-07-30 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-07 FADY MALIK Officer 24,500 $2.10M 2026-07-07 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-01 ROBERT BLUM Director, Officer 52,500 $4.47M 2026-07-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-29 Sung Lee Officer 9,503 $781.1K 2026-06-29 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-26 Sung Lee Officer 6,695 $541.0K 2026-06-26 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-04 Earnings results EDGAR
2026-08-28 Other events EDGAR
2026-08-13 Other events EDGAR
2026-08-06 Earnings results EDGAR
2026-05-27 Shareholder vote results EDGAR
2026-05-08 Other events EDGAR
2026-05-05 Earnings results EDGAR
2026-05-05 Other events EDGAR
2026-02-24 Earnings results EDGAR
2026-02-17 Other events EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-26 0001193125-26-076495 EDGAR
2025-02-27 0000950170-25-029206 EDGAR
2024-02-28 0000950170-24-022256 EDGAR
2023-03-01 0000950170-23-005515 EDGAR
2022-02-25 0001564590-22-007218 EDGAR
2021-02-26 0001564590-21-009467 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-04 0001193125-26-447408 EDGAR
2026-08-06 0001193125-26-338217 EDGAR
2026-05-05 0001193125-26-206364 EDGAR
2025-11-05 0001193125-25-267059 EDGAR
2025-08-07 0000950170-25-105108 EDGAR
2025-05-06 0000950170-25-064529 EDGAR
2024-11-07 0000950170-24-123283 EDGAR
2024-08-09 0000950170-24-094743 EDGAR
2024-05-10 0000950170-24-057805 EDGAR
2023-11-03 0000950170-23-058914 EDGAR
ETF Holders
121 ETFs hold CYTK
25 shown · $1.92B total exposure · 0.22% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.01% $293.2M — 2026-09-30
2 IJH iShares Core S&P Mid-Cap ETF iShares (BlackRock) 0.22% $270.1M $121.4B 2026-11-06
3 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.12% $206.3M — 2026-09-30
4 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.25% $187.9M $76.6B 2026-11-06
5 VBK Vanguard Morningstar Small-Cap Growth ETF Vanguard 0.26% $114.7M — 2026-09-30
6 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 1.14% $114.6M $10.0B 2026-11-05
7 VXF Vanguard Extended Market ETF Vanguard 0.11% $103.4M — 2026-09-30
8 TCAF T. Rowe Price Capital Appreciation Equity ETF Nport 1.34% $98.9M — 2026-06-30
9 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.44% $61.2M $13.9B 2026-11-06
10 MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust SPDR (State Street) 0.23% $59.0M $25.6B 2026-11-05
11 IBB iShares Biotechnology ETF iShares (BlackRock) 0.49% $54.1M $11.1B 2026-11-06
12 VTWO Vanguard Russell 2000 ETF Vanguard 0.29% $51.7M — 2026-09-30
13 XMMO Invesco S&P MidCap Momentum ETF Invesco 0.81% $49.0M — 2026-11-05
14 SCHA Schwab U.S. Small-Cap ETF Nport 0.20% $45.7M — 2026-08-31
15 SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF SPDR (State Street) 0.23% $42.4M $18.3B 2026-11-05
16 SCHM Schwab U.S. Mid-Cap ETF Nport 0.18% $26.6M — 2026-08-31
17 VHT Vanguard Health Care ETF Vanguard 0.11% $24.6M — 2026-09-30
18 IJK iShares S&P Mid-Cap 400 Growth ETF iShares (BlackRock) 0.24% $24.6M $10.2B 2026-11-06
19 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.30% $20.1M $6.6B 2026-11-05
20 IJJ iShares S&P Mid-Cap 400 Value ETF iShares (BlackRock) 0.20% $17.5M $8.6B 2026-11-06
21 IVOO Vanguard S&P Mid-Cap 400 ETF Vanguard 0.27% $15.3M — 2026-09-30
22 JSMD Janus Henderson Small/Mid Cap Growth Alpha ETF Janus 1.21% $12.2M $1.0B 2026-11-06
23 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.01% $9.7M $93.2B 2026-11-06
24 NUSC Nuveen ESG Small-Cap ETF Nport 0.64% $8.3M — 2026-07-31
25 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.05% $7.4M $13.7B 2026-11-06
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-7.22
TTM Revenue
$67.67M
TTM Net Income
$-894.00M
TTM Op. Cash Flow
$-555.45M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$28.62M$-198.76M$-1.50$-159.84M
Q1 '262026-03-31$19.36M$-206.03M$-1.67$-145.46M
Q4 '252025-12-31$17.75M$-183.03M$-1.50$-142.65M
Q3 '252025-09-30$1.94M$-306.18M$-2.55$-107.50M
Q2 '252025-06-30$66.77M$-134.37M$-1.12$-128.24M
Q1 '252025-03-31$1.58M$-161.38M$-1.36$-131.62M
Q4 '242024-12-31$16.93M$-150.02M$-1.26$-65.57M
Q3 '242024-09-30$463.00K$-160.54M$-1.36$-101.50M
Q2 '242024-06-30$249.00K$-143.32M$-1.31$-99.31M
Q1 '242024-03-31$835.00K$-135.64M$-1.33$-129.51M
Q4 '232023-12-31$1.67M$-136.90M$-1.38$-74.04M
Q3 '232023-09-30$378.00K$-129.42M$-1.35$-96.20M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
101.45
EV/EBITDA
—
EV/Sales
114.22
ROE
—
ROA
-46.5%
Div Yield
0.00%
FCF Yield
-8.09%
Debt/Equity
—
Current Ratio
—
Market Cap
$6.86B
as of 2026-11-09

CYTK vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 45.9 +45.5% +31.0% 27
ISRG Intuitive Surgical Inc. $160.0B 55.8 +20.5% −17.9% 18
VRTX Vertex Pharmaceuticals Inc $138.7B 35.4 +10.5% +21.6% 63
RVMD Revolution Medicines, Inc. Common Stock $41.6B — — +151.5% 65
GH Guardant Health, Inc. Common Stock $20.4B — +42.7% +56.9% 25
TWST Twist Bioscience Corporation Common Stoc $8.0B — +17.8% +320.9% 99
CYTK Cytokinetics Inc. $7.5B — −21.1% −10.1% 53
COGT Cogent Biosciences, Inc. Common Stock $5.5B — — −3.5% 94
TVTX Travere Therapeutics, Inc. Common Stock $4.8B — +49.4% +28.5% 22
Peer median $31.0B 45.9 +31.6% +29.7% 45

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
18.63M
SI % of Float
15.39%
Days to Cover
8.71
Short Vol Ratio
47.1%
Free Float
121.07M
Float %
97.3%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24